



#11  
Amdt.c  
11/21/02

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: JESUS PRIETO VALTUENA, et al

SERIAL NO.: 09/674,445

GROUP NO.: 1647

FILED: NOVEMBER 1, 2000

EXAMINER: JEGATHEESAN SEHARASEYON

FOR: UTILIZATION OF INTERFERON ALPHA 5 IN THE TREATMENT OF VIRAL  
HEPATOPATHIES

Attorney Docket No.: U 013039-2

RECEIVED

NOV 07 2002

Assistant Commissioner for Patents  
Washington, D.C. 20231

TECH CENTER 1600/2900

AMENDMENT

In response to the Official Action of July 30, 2002, please amend the  
application as follows:

IN THE CLAIMS

Please amend the following claim:

**CERTIFICATION UNDER 37 C.F.R. 1.8(a) and 1.10\***

*(When using Express Mail, the Express Mail label number is mandatory;  
Express Mail certification is optional.)*

I hereby certify that, on the date shown below, this correspondence is being:

**MAILING**

☒ deposited with the United States Postal Service in an envelope addressed to the Assistant Commissioner for  
Patents, Washington, D.C. 20231.

**37 C.F.R. 1.8(a)**

☒ with sufficient postage as first class mail.

**37 C.F.R. 1.10\***

☐ as "Express-Mail Post Office to Addressee"  
Mailing Label No. \_\_\_\_\_  
(mandatory)

**TRANSMISSION**

☐ transmitted by facsimile to the Patent and Trademark Office.

Signature

Date: October 29, 2002

CLIFFORD J. MASS

(type or print name of person certifying)

**\*WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. 1.10(b).  
"Since the filing of correspondence under § 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.